Source comparison
PT-141 MC4R Agonism: Mechanism Comparison
PT-141 MC4R agonism differs from other melanocortin-targeted therapies in receptor selectivity, tissue distribution, and clinical application. The table below compares PT-141 to setmelanotide and alpha-MSH across key pharmacological parameters. PT-141 (Bremela
This comparison does not assign a generated winner or score.
- PT-141 MC4R agonism differs from other melanocortin-targeted therapies in receptor selectivity, tissue distribution, and clinical application. The table below compares PT-141 to setmelanotide and alpha-MSH across key pharmacological parameters.
- PT-141 (Bremelanotide)
- 2.4 nM
- High (1.9 nM)
- Hypoactive sexual desire disorder
- Moderate (18% reduction in preclinical models)
- 2.7 hours
- Dual MC3R/MC4R agonist with short duration. Metabolic effects present but transient
- Setmelanotide
- 0.27 nM
- Moderate (20 nM)
- Genetic obesity (POMC/LEPR deficiency)
- High (25.6% body weight reduction at 52 weeks)
- 1.7 hours
- Selective MC4R agonist with maximal satiety signaling. FDA-approved for rare obesity syndromes
- Alpha-MSH (Endogenous)
- 1.1 nM
- High (0.9 nM)
- None (endogenous peptide)
- Variable (depends on POMC neuron tone)
- Minutes (rapid degradation)
- Non-selective melanocortin agonist. Activates all five receptor subtypes including MC1R (tanning)
- Melanotan II
- 1.4 nM
- Moderate (12 nM)
- None (research peptide)
- Moderate to high (20–28% in rodent models)
- 2–3 hours
- Broad melanocortin agonist with MC1R activity. Produces tanning and sexual effects
- Setmelanotide's tenfold higher MC4R affinity explains its superior efficacy for appetite suppression, but also its higher incidence of nausea. PT-141's balanced MC3R/MC4R profile makes it effective for arousal pathways (which require both receptors) while producing milder metabolic effects. Alpha-MSH lacks selectivity entirely, activating MC1R and causing hyperpigmentation. This is why synthetic analogs like PT-141 were developed.